As applications for artificial intelligence continue to refine and expand, leaders across industries are transforming their organizations by developing use cases for new features and processes.
According to a 2024 Honeywell report, more than 90% of industrial AI leaders are discovering new use cases for AI during implementation, and more than 50% report that their C-suite has already decided to expand AI use at their organizations.
Amid this sustained enthusiasm for AI, the NVIDIA AI Summit in downtown Washington, D.C., brought together experts in robotics, the public sector and more to discuss the current state of AI with an eye toward emerging possibilities.
Tuesday, attendees interested in the U.S. government’s approach to healthcare innovation heard from Renee Wegrzyn, director of ARPA-H, or Advanced Research Projects Agency for Health. She spoke about how ARPA-H got its start, its focus areas and the role of public-private partnerships along with Rory Kelleher, global business development lead for healthcare and life sciences at NVIDIA.
PREPARE: Expert guidance helps healthcare organizations achieve meaningful transformation with AI.
What Is ARPA-H and What Role Does It Play in Healthcare Innovation?
The launching of Sputnik by the Soviet Union in 1957 caught the U.S. by surprise, and it led to the establishment of the Defense Advanced Research Projects Agency (DARPA) to position the U.S. to have a more proactive posture regarding technological advances.
Similarly, the Biden administration established ARPA-H in 2022 to lead breakthroughs in the healthcare space with the aim of “accelerating better health outcomes” for everyone, Wegrzyn said. ARPA-H brings on program managers for limited terms to tackle key issues in health, such as specific chronic illnesses.
“ARPA-H lives in the future, and so do we at NVIDIA,” Kelleher said as he introduced the agency during the session. “We are in the business of time machines, trying to help make what’s impossible possible.”